Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Options

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Dec 05, 2021 4:46pm

88 Views

Post# 34200420

RE:RE:RE:Options

So you sre ok with that?

SPCEO1 wrote: Maybe the options grants now tells us why they have been pretty quiet about the trial - they needed to get to the new fiscal year to grant options at a low price before announcing good results on the phase 1a or a partnership in cancer (or maybe even NASH).

palinc2000 wrote:
Tons of options at a very low low price!!!! I think the timing for the option grant is much earlier Than previous years????
Is there a rush!!!!
The sickening part is that apparently all you need to qualify to receive options is to be on the payroll

.

Thao977 wrote: Options has been granted on december 1st. At $4.21 CAN